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Abstract
Background: Numerous practitioners of both conventional and complementary and alternative
medicine throughout North America and Europe claim that chelation therapy with EDTA is an
effective means to both control and treat cardiovascular disease. These claims are controversial,
and several randomized controlled trials have been completed dealing with this topic. To address
this issue we conducted a systematic review to evaluate the best available evidence for the use of
EDTA chelation therapy in the treatment of cardiovascular disease.
Methods: We conducted a systematic review of 7 databases from inception to May 2005. Hand
searches were conducted in review articles and in any of the trials found. Experts in the field were
contacted and registries of clinical trials were searched for unpublished data. To be included in the
final systematic review, the studies had to be randomized controlled clinical trials.
Results: A total of seven articles were found assessing EDTA chelation for the treatment of
cardiovascular disease. Two of these articles were subgroup analyses of one RCT that looked at
different clinical outcomes. Of the remaining five studies, two smaller studies found a beneficial
effect whereas the other three exhibited no benefit for cardiovascular disease from the use of
EDTA chelation therapy. Adverse effects were rare but those of note included a few cases of
hypocalcemia and a single case of increased creatinine in a patient on the EDTA intervention.
Conclusion: The best available evidence does not support the therapeutic use of EDTA chelation
therapy in the treatment of cardiovascular disease. Although not considered to be a highly invasive
or harmful therapy, it is possible that the use of EDTA chelation therapy in lieu of proven therapy
may result in causing indirect harm to the patient.
Background
Chelation therapy, a program of repeated intravenous
administration of ethylene diamine tetraacetic acid
(EDTA), often given in combination with vitamins and
minerals, has been touted as a safe alternative treatment
for atherosclerotic vascular disease [1-3]. As this is a non-
conventional therapy, there is no universally recognized
standard protocol. Most protocols, however, share a
degree of similarity. A typical protocol might consist of 30
intravenously administered solutions of 3 grams of diso-
dium EDTA with concomitant administration of varying
levels of ascorbic acid, B-vitamins, heparin, and the
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minerals magnesium, copper, zinc, selenium and manga-
nese delivered over 1.5 to 3 hours in 500 ml to 1000 ml
of normal saline. Therapy is often delivered on a weekly
or biweekly basis and may be followed up with a less fre-
quent maintenance schedule.
There is a very strong market for this therapy with out-of-
pocket costs for the use of EDTA to treat cardiovascular
disease estimated to range from $400 million to $3 bil-
lion annually in the United States [4,5]. The use of chela-
tion therapy for cardiovascular disease appears to
contradict conventional medical thought, however, as
three systematic reviews of clinical trials have concluded
that chelation therapy is not supported by the evidence
[1,2,6]. In contrast, one early meta-analysis of uncon-
trolled trials and unpublished data claimed that EDTA
chelation therapy effectively improved the symptoms of
cardiovascular disease in over 80% of cases [7].
There is continued controversy as to the use of this therapy
and a substantial amount of press given to it in popular
non-peer reviewed literature and on the Internet. Consid-
ering the continued widespread usage and interest in
EDTA chelation therapy we have endeavored to review the
most current state of the evidence in order to provide an
update on this contentious and clinically relevant issue.
Methods
Search strategy
We searched the following databases, from inception to
May 2005: MedLine, EMBASE, Cochrane controlled trials
register (CENTRAL), AMED (Alternative Medicine);Alt
HealthWatch;Pre-CINAHL;CINAHL;and the Nursing and
Allied Health Collection. In addition we searched for
unpublished and on-going trials through Clinicaltrials.
gov and the National Research Register (UK). To be
included in this review, a trial had to be a randomized
controlled trial assessing EDTA in humans at risk for car-
diovascular disease. We excluded non-randomized trials
and pharmacokinetic studies. No limits based on lan-
guage were imposed. Two reviewers (DS and PW) inde-
pendently assessed the articles for inclusion and outcome
data. In the case of disagreement, arbitration was sought
from EM.
A more detailed description of the search strategy used
and the results are presented [see additional file 1].
Authors of some of the trials were contacted to solicit their
interpretation of the review and also to comment on any
criticism that we had found in non-peer reviewed
literature.
Data abstraction
We abstracted outcome data on ECG tests, exercise tests
including treadmill tests, cycling time, time to ischemia,
pain free and maximal walking distances, subjective
symptoms of angina, ankle brachial indices, digital sub-
traction angiograms, transcutaneous oxygen tension,
blood cholesterol levels, and quality of life measures. We
planned to conduct a meta-analysis, however, the limited
number of trials, their clinical heterogeneity, and the var-
iability of outcomes made pooling impossible. We
abstracted quality criteria data from each of the RCTs
assessed based on randomization, sample size determina-
tion, dropouts, intention to treat, blinding, and allocation
concealment.
Results
Main findings
We found a total of fourteen studies for further analysis
[4,8-20]. Of these, we excluded seven, as they were either
review articles or non-randomized studies [8-14]. Seven
studies of randomized controlled trials have been
included in this systematic review [4,15-20]. Of the seven
manuscripts, five were of distinct sample populations
[4,16-18,20], with three of the trials analyzing data from
only one participant sample [15,16,19]. Except for one
trial published in Danish, all trials were published in Eng-
lish between 1963 and 2002. The data from the Danish
trial was also published in English, however, thereby not
requiring translation or inclusion. All included trials were
conducted in the United States, Canada, Denmark, New
Zealand, or Germany.
Of the five sample populations tested, two studies (total n
= 19) demonstrated a beneficial effect of EDTA chelation
therapy on cardiovascular disease measures and three
(total n = 269) did not.
Study characteristics and adverse effects
Since the most recent systematic review, a Cochrane
review, by Villaruz et al., 2002 [6], there has been one ran-
domized controlled clinical trial on the effect of EDTA on
cardiovascular disease. The conclusion found by Villaruz
et al was that 'there is insufficient evidence to decide on
the effectiveness or ineffectiveness of chelation therapy in
improving clinical outcomes of patients with atheroscle-
rotic cardiovascular disease' [6].
The most recent placebo-controlled trial conducted by
Knudtson and colleagues in 2002 [4] explored the effect
of chelation therapy on ischemic heart disease. When
compared to placebo, a total of 33 rounds of EDTA treat-
ment per patient was found to have no effect in any of the
outcomes measured [see additional file 2]. Both groups
exhibited improvements from baseline but this was inde-
pendent of EDTA use.
Two of the earliest randomized controlled trials, by Kitch-
ell et al., 1963 [17] and Olszewer et al., 1990 [18], foundBMC Cardiovascular Disorders 2005, 5:32 http://www.biomedcentral.com/1471-2261/5/32
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EDTA chelation therapy to have a beneficial effect on car-
diovascular risk profiles when compared to control. In the
first trial by Kitchell et al., 50% of the active group experi-
enced improved ECG readings after 6 and 12 weeks fol-
lowing the final treatment. This crossover trial was halted
early because 3 of the 5 members in the placebo group
dropped out due to a lack of improvement. In the trial by
Olszewer et al. (1990), the code was broken early because
the exercise measures and the ankle brachial blood pres-
sure index all showed dramatic improvements in the che-
lation group [see additional file 2]. Of all the trials
analyzed, however, these studies used the least number of
participants, with sample sizes of 9 and 10 respectively.
Since the two positive trials by Kitchell and Olszewer,
three larger trials have been completed. None of the more
recent trials has indicated any benefit from EDTA therapy
on cardiovascular disease. One group of investigators,
Guldager et al., 1992 [16], tested 153 patients with inter-
mittent claudication for a number of clinical outcomes
[see additional file 2]. None of these outcomes demon-
strated evidence of improvement using parenteral EDTA
chelation. Two subsets of this initial sample were ana-
lyzed separately; one for digital angiograms and transcu-
taneous oxygen profiles [19], and one for blood
cholesterol levels [15]. In neither of these outcomes was
there any evidence of improvement dependent the inter-
vention alone. In the trial by Van Rij et al., 1994 [20], 32
patients were tested for similar outcomes with the same
negative findings. As described above, the most recent
trial by Knudtson et al., 2002 did not find any evidence of
efficacy in the treatment of 84 patients with coronary
artery disease through EDTA chelation therapy [4].
We assessed for adverse effects amongst the trials and
found only a few cases of adverse events that might be
attributed to the EDTA [see additional file 2]. In the EDTA
treatment (vs. control) groups, one trial had a single (zero
controls) case of potential kidney toxicity in a population
of 84 [4] and in another trial, eight cases (two controls) of
faintness and 12 cases of hypocalcemia (one control) in a
population of 153 were found [16]. No other adverse
effects were noted in any of the RCTs.
Study quality
In an assessment of the articles for quality criteria, two of
the trials did not describe randomization [15,17]; sample
size determination was only described in two trials [4,20];
drop outs were excessive in one [17]; intention to treat
analysis was performed in four trials [4,18-20]; blinding
was inadequate in two of the trials [17,18]; and allocation
concealment was only adequate in one trial [4]. A sum-
mary of quality criteria findings is listed in table 1. The
two trials with the highest quality [4,20] were the most
recent and, as discussed above, found no evidence of effi-
cacy for EDTA chelation therapy in the treatment of
cardiovascular disease.
Table 1: Quality criteria of the randomized controlled trials assessed
Reference Randomization Sample size 
determination
Drop outs Intention to 
treat analysis
Blinding Allocation 
concealment
Kitchell 1963 [17] Not described 
(nor stated)
Not described 33% of the 
treatment group 
upon cross-over
No Allegedly 
participants 
blinded, but 
impossible to 
adequately assess
Unclear
Olszewer 1990 
[18]
Described Not described None Yes Initially double 
blinded but code 
was broken after 
10 treatments and 
study was 
completed with 
single blind for 
remaining 10 
treatments
Unclear
Sloth-Nielsen 
1991 [19]
Described Not described None Yes Double Unclear
Guldager 1992 
[16]
Described Not described 4 drop outs by 3 
months; 30 drop 
outs by 6 months
No Double: code 
broken at 3 
months
Unclear
Guldager 1993 
[15]
Not described Not described Not mentioned No Double Unclear
Van Rij 1994 [20] Described Yes None Yes Double Unclear
Knudtson 2002 [4] Described Yes 4 in placebo, 2 in 
treatment group
Yes Double Well describedBMC Cardiovascular Disorders 2005, 5:32 http://www.biomedcentral.com/1471-2261/5/32
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Discussion
The overall evidence on EDTA chelation therapy argues
against any clinical benefit with respect to cardiovascular
disease. The evidence that we were able to find in support
of EDTA chelation for cardiovascular disease relies almost
entirely on uncontrolled trials and a large body of anecdo-
tal evidence. Given the parameters of the evidence so far,
and in keeping with patient values, it is encouraging that
the NIH is funding a large simple trial. A 5-year multi-
center randomized placebo-controlled trial will hopefully
deliver a conclusive answer on the question of whether or
not intravenous EDTA infusion has any role in the treat-
ment of cardiovascular disease. Until such time, clinicians
should openly discuss the use of complementary and
alternative medicine and specifically chelation therapy
with patients in an informed and non-judgmental man-
ner. Clinicians should also discuss potential risks associ-
ated with EDTA chelation therapy and the current lack of
evidence supporting it use in cardiovascular disease.
Proposed mechanisms of action for the reversal of cardio-
vascular disease by EDTA include: calcium chelation
resulting in dissolution of atheromatous plaques, free rad-
ical scavenging action, reduction of total body iron stores,
cell membrane stabilization, arterial dilatation due to cal-
cium channel blocking action, improvement of arterial
wall elasticity and increased production of nitric oxide
[4,21]. Critics have taken issue with some of these mech-
anisms, however, claiming the use of outdated concepts
on the pathophysiology of atherosclerosis and for
instance, the inability of EDTA, a water soluble com-
pound, to effectively complex with plaque calcium [3].
Given the widespread usage of EDTA chelation therapy,
an assessment of its safety is crucial. EDTA is responsible
for a wide range of potential side effects including gas-
trointestinal and musculoskeletal complaints, diaphore-
sis, fever, leukopenia, thrombocytopenia, kidney damage,
mineral depletion, and hypocalcemia [19,22-24]. With
Flow-chart detailing study selection and exclusion for systematic review Figure 1
Flow-chart detailing study selection and exclusion for systematic review.
x 374 articles excluded as irrelevant or
duplicate papers based on title and/or
abstract
x 14 articles retrieved for further
analysis
x 7 articles rejected due to being
review, duplicate data, and/or o
randomized trials 
fn o n -
x 7 studies included in the systematic review 
(including data from 5 separate trials)
x 2 studies analysed data from subpopulations of
the larger study
x 388 articles screened for inclusionBMC Cardiovascular Disorders 2005, 5:32 http://www.biomedcentral.com/1471-2261/5/32
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proper dose control and assessment of kidney function,
however, EDTA is not considered to be a particularly high-
risk therapy and there is little doubt that it is safer than
coronary bypass surgery. However, if EDTA has no efficacy
beyond placebo, then the possibility of adverse effects, the
cost of treatment, and potential to avoid greater risk may
well result in unjustifiable morbidity and mortality.
There are several limitations to consider in our review. We
cannot determine to what extent publication bias has
affected our results. Empirical evidence has shown that
negative trials in CAM and other fields are less likely to be
published [25]. Claims have been made however, that evi-
dence in favor of EDTA chelation therapy may have been
suppressed [26]. To mitigate as much as possible against
these circumstances, we conducted thorough systematic
searches of the literature. We contacted some, but not all
of the authors of the studies to confirm our interpretation
of the results. It may be that authors of original studies
excluded important information from the published
manuscripts in order to reduce the page length or to fol-
low reviewers' suggestions [27]. In many of the trials there
was a significant improvement in outcome measures for
both control groups and chelation groups. This is a clear
indication of the need to conduct controlled trials in order
to pick up a type I error that might mistakenly attribute
efficacy to the therapy in question.
There is a large body of literature to support the use of
EDTA in the treatment of cardiovascular disease; however,
the vast majority of the literature relies on uncontrolled
evidence. Supporters of EDTA chelation therapy have lev-
ied a number of criticisms against some of the RCTs
assessed in this review. These criticisms include but are
not limited to: too short of a treatment schedule, claims of
incorrect statistical manipulation of the data, improper
randomization, and high dropout rates [26,28-30]. The
earliest trials incorporated 20 treatments of chelation
therapy and the American College for Advancement in
Medicine (ACAM), considered an authority in chelation
therapy, claims that at least 30 treatments may be required
for improvements to be noted. In the most recent study by
Knudston et al., 2002, however, a protocol involving 33
treatment sessions were used and no positive therapeutic
effect was found. In our review we included quality crite-
ria and did not find evidence of any bias, however, we did
not obtain the raw data needed to conduct an independ-
ent reanalysis.
Conclusion
The findings of this systematic review should be of interest
to clinicians and patients alike. The use of EDTA by
patients as a treatment for cardiovascular disease and as
an adjunct or alternative to surgery is not supported by the
highest quality of evidence. Considering the cost incurred
by patients who use EDTA chelation therapy and the
potential for harm associated with any intravenous inter-
vention including the potential for adverse effects attrib-
utable directly to EDTA, clinicians should inquire about
patient use and highlight the lack of evidence to support
its usage.
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